Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus
Objective: The risk of fracture is higher in people with than without diabetes. Because bone mineral density is not a good predictive marker of bone strength in people with diabetes, another surrogate is needed. Sclerostin is an inhibitor of bone formation and is secreted mainly by osteocytes. This...
Main Authors: | Eisuke Tomatsu, Megumi Shibata, Yasumasa Yoshino, Sahoko Sekiguchi-Ueda, Ayako Kakita, Takeshi Takayanagi, Masaki Makino, Nobuki Hayakawa, Atsushi Suzuki |
---|---|
Format: | Article |
Language: | English |
Published: |
Fujita Medical Society
2018-02-01
|
Series: | Fujita Medical Journal |
Subjects: | |
Online Access: | https://www.jstage.jst.go.jp/article/fmj/4/1/4_2017006/_pdf/-char/en |
Similar Items
-
Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover
by: Yentl Huybrechts, et al.
Published: (2023-01-01) -
The effect of regular fitness training, sex hormones, and turnover of selected bone markers on sclerostin levels in young women
by: Ryszard Plinta, et al.
Published: (2020-10-01) -
The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
by: Arkadiusz Zygmunt, et al.
Published: (2021-10-01) -
Antitumor Effect of Sclerostin against Osteosarcoma
by: Hirokazu Ideta, et al.
Published: (2021-11-01) -
Sclerostin as a novel marker of bone turnover in athletes
by: A Zagrodna, et al.
Published: (2016-02-01)